Multi-organ landscape of therapy-resistant melanoma

Metastasis and failure of present-day therapies represent the most common causes of mortality in patients with cutaneous melanoma. To identify the underlying genetic and transcriptomic landscapes, in this study we analyzed multi-organ metastases and tumor-adjacent tissues from 11 rapid autopsies after treatment with MAPK inhibitor (MAPKi) and/or immune checkpoint blockade (ICB) and death due to acquired resistance .. Continua a leggere

Neoadjuvant immunotherapy for melanoma is now ready for clinical practice

Neoadjuvant therapy — the use of chemotherapy and/or radiotherapy before a primary course of treatment — was originally developed to improve the operability of tumors, for example in breast cancer, lung cancer and sarcomas. With the advent of systemic immune … Continua a leggere

Impact of second opinion pathology review in the diagnosis and management of atypical melanocytic lesions: A prospective study of the Italian Melanoma Intergroup (IMI) and EORTC Melanoma Group

The clinical value of an expert pathological review in patients with an atypical melanocytic lesion diagnosis remains unclear. Herein, we evaluate its impact in a prospective clinical study. Patients with newly diagnosed or suspected atypical melanocytic proliferations and challenging skin tumours were reviewed prospectively by a specialised dermatopathologist through the nationwide … Continua a leggere

Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial

In the phase II/III RELATIVITY-047 trial, a novel fixed-dose combination (FDC) of nivolumab plus relatlimab (NIVO + RELA; a programmed death-1 and a lymphocyte-activation gene 3 inhibitor, respectively) significantly improved progression-free survival (PFS) versus NIVO in patients with previously untreated unresectable or metastatic melanoma (median follow-up, 13.2 months) with stable health-related quality of life (HRQoL) …  Continua a leggere

Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma

Metformin is a commonly prescribed and well-tolerated medication. In laboratory studies, metformin suppresses BRAF wild-type melanoma cells but accelerates the growth of BRAF-mutated cells. This study investigated the prognostic and predictive value of metformin, including with respect to BRAF mutation status, in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 randomised controlled trial … Continua a leggere

CURA.r.t.e.
Roma, 14 giugno 2023

Italiani all’ASCO – I parte
I mercoledì dell’oncologia
Webinar, 14 giugno 2023 dalle 17.00 alle 18.15

Tumori dell’apparato Genitourinario: Evoluzione della Terapia Oncologica
Ancona, 15 giugno 2023

Preparing for the best match
Roma, 15 giugno 2023

Recommendations on integration of radiation therapy with targeted treatments for breast cancer consensus meeting
Firenze, 16 – 17 giugno 2023

Controversie nel trattamento del carcinoma mammario
Ferrara, 16 giugno 2023

Neoplasia della mammella: il traguardo all’orizzonte 
Montegranaro (FM), 16 giugno 2023

Oncogene Addicted International Lung Cancer Summit
Ravenna, 16 – 17 giugno 2023

La rivoluzione della terapia medica nel NSCLC
Palermo, 19 giugno 2023

Precision & Innovation in Oncology 
Firenze, 19 giugno 2023

Clinical trial academy: corso di alta formazione in ricerca clinica
Bertinoro (FC), 19 – 21 giugno 2023

Italiani all’ASCO – II parte
I mercoledì dell’oncologia
Webinar, 21giugno 2023 dalle 17.00 alle 18.15

Aggiornamenti in oncologia. I tumori del polmone oncogene addicted
Rome, 21 giugno 2023

2023 News in Oncology from USA to Italy
Bologna / FAD sincrona, 22 – 23 giugno 2023

5° Corso IEO sui tumori neuroendocrini funzionanti
Assago (MI), 26 giugno 2023

44th International Conference on Screening for Lung Cancer
Verona, 28 – 30 giugno 2023

From Chicago to Pesaro&Urbino: update in oncologia
Urbino, 30 giugno 2023

Supportive care & quality of life
Padova, 30 giugno – 1° luglio 2023

New perspectives of clinical research in gynecological cancer
Pisa, 30 giugno – 1° luglio 2023

Tumore della mammella: Il punto di vista della Donna
Bari, 30 giugno – 1 luglio 2023

Congresso Mesotelioma- Let’s network
Milano, 7 Luglio 2023

Convegno Nazionale AIOM Giovani Oncologi
Perugia, 7 – 8 luglio 2023

Nuove frontiere e algoritmi di trattamento nel colangiocarcinoma
I mercoledì dell’oncologia
Webinar ECM, 12 luglio 2023 dalle 17.00 alle 18.15

XXV Congresso Nazionale AIOM
Roma, 10 – 12 novembre 2023